Odwala kuyankha bwino latsopano yogwira zilonda zam`matumbo mankhwala

Odwala omwe ali ndi matenda a ulcerative colitis (UC) omwe adatenga mirikizumab adapeza chiwongolero chachipatala pakatha milungu 12 poyerekeza ndi odwala omwe adatenga placebo pa kafukufuku wofunikira wa LUCENT-1 Phase 3 wa Eli Lilly ndi Company. Odwala omwe adatenga mirikizumab adapezanso kusintha kwakukulu pazotsatira zazikulu zachiwiri kuphatikiza miyeso yachipatala, symptomatic, endoscopic ndi histologic (ma cell cell of tissue), poyerekeza ndi omwe amatenga placebo. Zotsatira za phunziro loyamba la Lilly la kulowetsa m'kalasi likuperekedwa pafupifupi ku 17th Congress ya European Crohn's and Colitis Organization (ECCO), yomwe ikuchitika Feb. 16-19, 2022.        

"Anthu omwe ali ndi zilonda zam'mimba amakhala ndi kutupa kwa mucosal m'matumbo, komwe kumayambitsa magazi m'matumbo, kumayenda pafupipafupi kupita kuchipinda chosambira komanso kufunikira koyenda mwachangu," adatero Geert D'Haens, M.D., Ph.D., wolemba wamkulu komanso Pulofesa. Gastroenterology ku Amsterdam University Medical Centers. "Mirikizumab imatha kuchepetsa kutupa kwambiri, kuthandiza anthu kuti akhululukidwe komanso kuchepetsa kufulumira kwa matumbo, zomwe ndi nkhani yatsopano, yokhudzana ndi odwala zomwe sizinaphunziridwepo m'mayeso a Gawo 3 a ulcerative colitis."

Kuphunzira kwapadziko lonse kwa odwala 1,162 kunaphatikizapo odwala omwe sanayesepo mankhwala a biologic (biologic-naïve) ndi odwala ovuta omwe adatengapo kale biologic yomwe inalephera. Mmodzi mwa odwala anayi omwe amathandizidwa ndi mirikizumab (24.2%, n = 210/868) adakwaniritsa chikhululukiro chachipatala pakatha milungu 12, poyerekeza ndi m'modzi mwa asanu ndi awiri pa placebo (13.3%, n = 39/294, p=0.00006), kusonyeza mpumulo wabwino wa zizindikiro ndi kuthetsa kapena pafupi kuthetsa kutupa. Pafupifupi magawo awiri mwa atatu a odwala omwe amamwa mirikizumab (63.5%, n = 551/868) adalandira chithandizo chamankhwala, poyerekeza ndi ochepera theka la odwala omwe amathandizidwa ndi placebo (42.2%, n=124/294, p<0.00001). Kuti mupeze njira, onani gawo la "About the LUCENT-1 Study" pansipa.

Pafupifupi theka la odwala omwe amatenga mirikizumab (45.5%, n = 395/868) adalandira kukhululukidwa kwazizindikiro pakatha milungu 12, poyerekeza ndi ochepera gawo limodzi mwa magawo atatu a odwala omwe adatenga placebo (27.9%, n = 82/294, p <0.001). Kumayambiriro kwa milungu inayi, oposa mmodzi mwa odwala asanu omwe adatenga mirikizumab (21.8%, n = 189/868) adawona kusintha kwachangu kwazizindikiro zawo, poyerekeza ndi pafupifupi mmodzi mwa odwala asanu ndi atatu omwe adatenga placebo (12.9%, n = 38) /294, p<0.001).

Patangotha ​​​​masabata awiri ndikupitilira milungu 12, odwala omwe amathandizidwa ndi mirikizumab adachepetsedwa kwambiri pamlingo wa 11-points m'matumbo mwachangu. Pamasabata a 12, odwala anali ndi kuchepa kwapakati pa mfundo za 2.59 (2.32 mpaka 2.85), poyerekeza ndi kuchepetsa kwapakati pa 1.63 (1.18 mpaka 2.09) kwa odwala omwe ali ndi placebo (p <0.00001). Mapeto a matumbo a 2-sabata anali atafotokozedweratu koma sanali oyendetsedwa mochulukira.

Mbiri yonse yachitetezo inali yofanana ndi ya maphunziro am'mbuyomu a mirikizumab ku UC komanso yogwirizana ndi ma antibodies ena a anti-IL-23p19 m'malo ena achirengedwe. Odwala omwe amatenga mirikizumab, poyerekeza ndi omwe ali pa placebo, adanenanso za kuchepa kwa zochitika zowopsa (mirikizumab: 2.8%, n = 27; placebo: 5.3%, n = 17) ndipo sakanatha kusiya phunzirolo chifukwa cha zovuta. mirikizumab: 1.6%, n=15; placebo: 7.2%, n=23).